• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL AMPLATZER DUCT OCCLUDER II; OCCLUDER, PATENT DUCTUS, ARTERIOSUS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL AMPLATZER DUCT OCCLUDER II; OCCLUDER, PATENT DUCTUS, ARTERIOSUS Back to Search Results
Catalog Number UNK AMPLATZER DUCT OCCLUDER II
Device Problems Off-Label Use (1494); Patient Device Interaction Problem (4001)
Patient Problems Myocardial Infarction (1969); Obstruction/Occlusion (2422); Thrombosis/Thrombus (4440)
Event Date 01/01/2005
Event Type  Injury  
Manufacturer Narrative
Literature article: intermediate and long-term follow-up of transcatheter closure of congenital coronary cameral fistulas in infants and children: experience from a single center.Summarized patient outcomes/complications of amplatzer duct occluder were reported in a research article in a subject population with multiple co-morbidities including coronary artery aneurysms (caas),transcatheter closure (tcc) of coronary cameral fistulas (ccfs), congenital heart disease, murmur, and congestive heart failure.Some of the complications reported were acute inferior myocardial infarction, large residual shunt, chest pain, dyspnea, complete right coronary artery occlusion, and thrombus; these complications are anticipated for the procedure and subject population.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device or individual patient information was received for analysis.Based on the available information, the root cause of the reported event could not be conclusively determined.Please note, per amplatzer¿ duct occluder, instructions for use, "the amplatzer¿ duct occluder is indicated for patients with patent ductus arteriosus." this is considered as an off-label use of the device.However, it was unable to determine if the off-label use contributed to the reported incident.Therefore, a letter will not be provided to address the deviation from the ifu.
 
Event Description
The article, ¿intermediate and long-term follow-up of transcatheter closure of congenital coronary cameral fistulas in infants and children: experience from a single center¿, was reviewed.The article presented a retrospective single center study on their experience with transcatheter closure (tcc) of coronary cameral fistulas (ccfs) in a large cohort of pediatric patients, focusing on technical aspects of the closure procedure and intermediate and long-term follow-up.Devices included in this study were coils (cook medical, bloomington, in, usa), amplatzer duct occluder ii (ado ii; abbott vascular, saint paul, minnesota, usa), amplatzer vascular plug/plug ii (avp/avp ii; abbott vascular), domestic vascular plug (starway medical technology, beijing, china), ventricular septal defect occluder (vsd occluder, lifetech scientific, shenzhen, china), atrial septal defect occluder (asd occluder, lifetech scientific), and patent ductus arteriosus occluder (pda occluder, lifetech scientific).The article concluded that tcc of ccfs in infants and children appears to be effective and is associated with a relatively low complication rate.Large ccfs and giant coronary artery aneurysms (caas) represent a higher risk of both acute and intermediate and long-term adverse events after closure.[the primary and corresponding author was zhiwei zhang, department of pediatric cardiology, guangdong cardiovascular institute, guangdong provincial people¿s hospital (guangdong academy of medical sciences), southern medical university, guangdong provincial key laboratory of south china structural heart disease, guangzhou, 510100, china, with corresponding email: drzhangzw@sohu.Com] the time frame of the study was from january 2005 to december 2019.A total of 81 patients were included in this study with 66 patients who underwent transcatheter closure (tcc).Of those who underwent tcc, 26 (39.4%) received an abbott device.The average age at time of procedure was 3.93 years, average weight was 15 kg, and the average gender was male.Comorbidities included congenital heart disease, recurrent respiratory infection, exertional dyspnea, chest pain, palpitation, murmur, congestive heart failure, growth retardation, non-specific ecg abnormalities, chamber enlargement, left ventricle or right ventricle dilation, coronary cameral fistula, coronary artery aneurysm.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AMPLATZER DUCT OCCLUDER II
Type of Device
OCCLUDER, PATENT DUCTUS, ARTERIOSUS
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ABBOTT MEDICAL REG# 2135147
5050 nathan ln n
plymouth MN 55442
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key17908927
MDR Text Key325336210
Report Number2135147-2023-04446
Device Sequence Number1
Product Code MAE
Combination Product (y/n)N
Reporter Country CodeCH
PMA/PMN Number
P020024
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 10/10/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/10/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK AMPLATZER DUCT OCCLUDER II
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/18/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-